

Credibility of Assumptions & Modelling

F2F 2026 Copenhagen

Modelling and simulation to improve decision-making in clinical development

“One task for the modeller is precisely that of finding those questions where a limited amount of work is likely to give significant benefits. It might be hard for some statistical scientists to accept that being too rigorous may be harmful. The model need not be perfect. What matters is that the work is good enough to help make the right decisions.”

Burman, Hamren, Olsson (2005)

Reminder: ICH M15

Table 1: Guideline Overview in Relation to MIDD Planning and M

MIDD Planning ¹ and Regulatory Interaction		Implementa	
Key Assessment Elements	Additional Considerations for Interaction with Regulators and to Inform Decision-making	Model Evaluation	
<ul style="list-style-type: none"> • Question of Interest • Context of Use • Model Influence • Consequence of Wrong Decision • Model Risk • Model Impact 	<ul style="list-style-type: none"> • Technical Criteria for Evaluating Model and Model Outcome³ • Appropriateness of Proposed MIDD <p>These should be documented (e.g., in a Model Analysis Plan [MAP]).</p>	<ul style="list-style-type: none"> • Verification • Validation and Applicability Assessment 	•
Section 2.1 and Appendix 1	Sections 2.2 and 4.1 and Appendix 1	Section 3	S

Note: Terms used in this table are defined in relevant Guideline sections

- Widens focus from “Probability of type-1 error” to “Consequence & probability of any wrong decisions”
- Improves transparency and enables cross-functional discussions

Activities

- Group initiated at F2F 2025
- Monthly meetings, clarifying scope and reviewing existing frameworks on assumptions & modelling.
- Presentation at EMA Bayes Workshop
- Session at EFSPi Regulatory Statistics Workshop
 - General agreement that ICH M15 fit-for-statistics
- Paper drafted to support roll-out

Closing out

- Paper draft on the sharepoint
 - Status: currently in author review
- ASA Regulatory Industry Workshop Sessions:
 - John Scott (FDA)
 - Million Tegenge (AZ, formerly FDA)
 - Alison Margolskee (Novartis)
 - **Open: Statistical presenter with industry application/motivation**
 - Utilization for (Dynamic) Bayesian Borrowing (Qualification Opinion)
 - Suggestions urgently requested, as information to be uploaded by 21st of April (Changes afterwards possible)
- **Remaining steps: Communication & Persistence**
 - Continue raising awareness → Task for all
 - Continue bringing the message to modelers internally and in reviews.